Hyman Scott

Hyman Scott, MD is a Volunteer Assistant Clinical Professor in the Department of Medicine at the University of California, San Francisco (UCSF) School of Medicine. His academic work focuses on HIV prevention, infectious diseases, and public health interventions, with particular emphasis on pre-exposure prophylaxis (PrEP) and sexually transmitted infection prevention strategies. Dr. Scott is affiliated with the Bridge HIV research program at UCSF, where he contributes to clinical trials and implementation science research.

Dr. Scott completed his medical education at Yale School of Medicine in 2006, followed by an Internal Medicine residency at UCSF in 2009, and an Infectious Diseases fellowship at UCSF in 2014. His training background provides him with strong clinical foundations in both internal medicine and infectious disease specialties, which informs his research in HIV prevention and sexual health.

Dr. Scott's research primarily centers on innovative approaches to HIV prevention, with significant contributions to the development and implementation of pre-exposure prophylaxis (PrEP) strategies. His work spans clinical trials of biomedical interventions, evaluation of mobile health applications for HIV prevention, and studies examining barriers to PrEP access and adherence. A notable aspect of his research program involves investigating doxycycline as post-exposure prophylaxis for bacterial sexually transmitted infections. Dr. Scott has also contributed to HIV vaccine research, examining novel delivery methods and adjuvant strategies to enhance immune responses.

Analysis of Dr. Scott's recent publications reveals a strong focus on translational research that bridges clinical science with public health implementation. His work spans multiple domains including clinical trials of biomedical HIV prevention tools, evaluation of digital health interventions, epidemiological studies of STI trends, and implementation science research to improve access to prevention services. A significant portion of his recent work examines the effectiveness of doxycycline for preventing bacterial STIs, representing an emerging area of research with important public health implications.

Dr. Scott has been involved in numerous high-impact clinical trials and research initiatives, including the HPTN 083 study evaluating long-acting cabotegravir for HIV prevention, the DoxyPEP study examining doxycycline for STI prevention, and multiple studies investigating mobile health applications for HIV testing and PrEP adherence. His collaborative approach is evident through his extensive co-authorship network spanning academic institutions, research networks, and public health organizations.